Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yuexin Xu"'
Publikováno v:
Current Pharmaceutical Design. 26:3171-3186
Background: Metastatic colorectal cancer (mCRC) is one of the most common and deadly cancers worldwide. For most patients diagnosed with mCRC and managed with 5-fluorouracil (5-FU)/leucovorin plus oxaliplatin (FOLFOX), the median survival time is sti
Autor:
Yuexin Xu, Xiaoxuan Du
Publikováno v:
Experimental and Therapeutic Medicine
Application of dexmedetomidine-assisted intravertebral anesthesia for elderly patients with hip replacement and its influences on T-lymphocyte subsets in peripheral blood were assessed. Eighty-six patients undergoing intravertebral anesthesia in hip
Autor:
Yuexin Xu, David G. Coffey, Edus H. Warren, Alicia J. Morales, Andrea M. H. Towlerton, Damian J. Green, Qian Wu, Sharon Ornelas
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 10, Pp 1-4 (2019)
Blood Cancer Journal
Blood Cancer Journal
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selective
Publikováno v:
Journal of bone and mineral metabolism. 39(6)
Osteoporosis is a common form of metabolic bone disease that is costly to treat and is primarily diagnosed on the basis of bone mineral density. As the influences of genetic lesions and environmental factors are increasingly studied in the pathologic
Publikováno v:
Turkish Journal of Fisheries and Aquatic Sciences. 20
Autor:
Benjamin Diamond, Edgar Gonzalez-Kozlova, Edus H. Warren, David G. Coffey, Sacha Gnjatic, Ola Landgren, Dickran Kazandjian, Damian J. Green, Trevor J. Pugh, Alexander M. Lesokhin, Francesco Maura, Yuexin Xu, Javier Diaz-Mejia, Ping Luo, Eric L. Smith, Yong Zhang, Hearn Jay Cho
Publikováno v:
Blood. 138:329-329
Background: The progression of multiple myeloma (MM) during ongoing therapy is driven by a complex interplay between tumor cells and their surrounding immune microenvironment. We were motivated to conduct a comprehensive and orthogonal investigation
Autor:
Damian J. Green, Trevor J. Pugh, Ola Landgren, Yuexin Xu, David G. Coffey, Edus H. Warren, Dickran Kazandjian, Sacha Gnjatic
Publikováno v:
Blood. 134:4367-4367
Introduction: Maintenance therapy with the immunomodulatory drug (IMiD) lenalidomide improves progression-free survival (PFS) and overall survival among patients with multiple myeloma (MM). It has been suggested that IMiDs enhance immune-mediated ant
Autor:
Lee D. Cranmer, Yongwoo David Seo, Ernest U. Conrad, Elizabeth T. Loggers, Yuexin Xu, Sean Mackay, Frank J. Hsu, Ryan B. O’Malley, Venu G. Pillarisetty, Kevin Morse, Gabrielle Kane, Edward Y. Kim, Stanley R. Riddell, Taylor Hain, Seth M. Pollack, Jing Zhou, Hailing Lu, Jeremy Patino, Robin L. Jones, Jan ter Meulen
Publikováno v:
Journal of Clinical Oncology. 36:71-71
71 Background: Soft tissue sarcomas (STS) are heterogeneous tumors which are morbid and lethal. G100 is under investigation in multiple clinical trials and contains a potent TLR4 agonist (oil-in-water emulsion of glucopyranosyl lipid A) that has been